CSL Limited stock falls after Phase 3 setback (OTCMKTS:CSLLY)

CSL Limited stock falls after Phase 3 setback (OTCMKTS:CSLLY)

cagkansayin

Australian biotech CSL Limited (OTCQX:CSLLY) fell ~4% on Monday, marking its biggest intraday loss in more than four months after its Phase 3 AEGIS-II trial, one of its key clinical programs, failed.

The global trial was designed to evaluate serum protein CSL112 against a placebo to reduce the risk of major adverse cardiovascular events such as stroke in patients after a heart attack (acute myocardial infarction).

The post CSL Limited stock falls after Phase 3 setback (OTCMKTS:CSLLY) first appeared on Investorempires.com.

 

Default Featured Image

Working longer won’t solve the retirement crisis — seniors need a ‘Gray New Deal’ to retire with dignity, this economist says | Investorempires.com

Read More | Teresa Ghilarducci is the author of the new book “Work, Retire, Repeat: The Uncertainty of Retirement in the New Economy.” – University of Chicago Press The Value Gap  is a MarketWatch interview series with business leaders, academics, policymakers and activists on reducing racial and social inequalities. Most Read from MarketWatch Teresa Ghilarducci […]